By Nathan Owens | July 31, 2026
In a landmark move for the domestic biopharmaceutical supply chain, contract development and manufacturing organization (CDMO) Resilience has announced a strategic $750 million investment, bolstered by a partnership with pharmaceutical giant Eli Lilly. The expansion is set to significantly bolster the production of GLP-1 (glucagon-like peptide-1) injectables, a class of drugs that has fundamentally altered the treatment landscape for type 2 diabetes and obesity.
The initiative is not merely a financial commitment; it represents a major industrial pivot. By dedicating substantial new capacity to these complex medications, Resilience is creating 400 specialized manufacturing jobs, reinforcing the U.S. Midwest’s growing status as the epicenter of the global injectable medicine market.
The Core Expansion: Scaling Complex Medicine
At the heart of this announcement is the scale of infrastructure development taking place in Blue Ash, Ohio. Resilience, which recently made waves by relocating its global headquarters from San Diego to the Cincinnati suburbs, operates nearly 1 million square feet of space across two primary facilities in the region.
The $750 million infusion is earmarked for the installation of high-tech sterile manufacturing lines, device assembly, and advanced packaging capabilities. As GLP-1 medications—such as those used in Mounjaro and Zepbound—require precise, sterile, and complex handling, the technical requirements for these facilities are among the most stringent in the pharmaceutical world. This investment ensures that Resilience can maintain the rigorous quality standards required by the FDA while meeting the explosive consumer demand that has historically outpaced supply.
A Chronology of the GLP-1 Surge
The current partnership between Resilience and Eli Lilly is the culmination of years of rapid market development. To understand the gravity of this $750 million investment, one must look at the timeline of the "GLP-1 era":
- 2021–2022: Clinical data reveals unprecedented efficacy for weight loss, leading to a surge in prescriptions. Global supply chains, accustomed to steady growth, are caught off guard by the sudden, massive demand.
- 2023: Eli Lilly and competitor Novo Nordisk begin massive capital expenditure programs. Resilience identifies a strategic opportunity to act as the primary manufacturing backbone for these innovators.
- Late 2025: Resilience signals a permanent shift in its corporate identity, prioritizing sterile injectable capacity in Ohio over its legacy West Coast footprint.
- July 2026: The official announcement of the $750 million expansion, effectively doubling down on the "Made in the USA" manufacturing model for critical obesity and diabetes care.
Supporting Data: The Economic Engine of Weight Loss
The motivation behind this massive expansion is rooted in hard data. According to analysis by Morgan Stanley, the global market for GLP-1 drugs is projected to climb to an astonishing $190 billion by 2035. This trajectory is fueled by three primary drivers:
- Clinical Expansion: As more insurance providers move to cover GLP-1 treatments, the patient population is expanding from those with comorbid diabetes to a broader segment of the population struggling with obesity.
- Oral Formulation Growth: While injectables remain the gold standard, the market is preparing for a transition toward oral versions of these drugs, requiring even more sophisticated, high-speed manufacturing lines.
- Broadened International Access: As major international markets begin to approve and integrate these drugs into their healthcare systems, the pressure on manufacturing facilities has shifted from local to global.
This growth is why Eli Lilly has committed over $16 billion in recent months to build massive facilities in Houston, Huntsville, Alabama, and Lehigh County, Pennsylvania, alongside its $4.5 billion expansion in Lebanon, Indiana. Resilience acts as the essential "force multiplier" in this ecosystem, providing the flexible, scalable manufacturing capacity that internal plants often cannot pivot to quickly enough.
Official Responses: A Strategic Vision
William Marth, President and CEO of Resilience, framed the investment as a national priority during his address to stakeholders. "We are proud of what we have built together with Lilly," Marth stated. "This new expansion is a testament to our ability to scale the production of complex medicines right here in Ohio. Our investment reflects our long-term commitment to building one of the largest and most advanced sterile injectable and device assembly and packaging operations in the United States."
The move to relocate the headquarters from San Diego to Blue Ash was the precursor to this investment, signaling that Resilience views the Ohio corridor as its long-term industrial home. By consolidating operations, the company has created a synergy between its administrative leadership and its factory floor, a rare alignment in the world of high-stakes contract manufacturing.
Implications: The Future of Biopharma Manufacturing
The implications of this partnership extend far beyond the 400 new jobs created in the Cincinnati area.
Reshoring the Supply Chain
The COVID-19 pandemic exposed the fragility of global drug manufacturing, particularly the reliance on overseas facilities for sterile components. By concentrating billions of dollars of investment into the American Midwest, companies like Lilly and partners like Resilience are effectively "reshoring" the most critical aspects of the modern medicine supply chain. This reduces the risk of geopolitical or logistical disruptions impacting patient access to life-saving medication.
The CDMO Model Evolution
Resilience is proof that the traditional CDMO (Contract Development and Manufacturing Organization) model is evolving. In the past, CDMOs were viewed as secondary partners. Today, they are essential stakeholders in the development of drug availability. By sharing the capital burden of building high-tech facilities, Resilience allows the "innovator" companies—the ones that discover the drugs—to focus their capital on R&D and clinical trials, while the CDMO handles the industrial heavy lifting.
The "Ohio Corridor" Effect
The regional impact is profound. With nearly 1,000 manufacturing workers already employed by Resilience in the Cincinnati area, the company has become a pillar of the local economy. The addition of 200 headquarters jobs alongside 400 manufacturing roles signals a robust economic future for the region, potentially attracting a cluster of ancillary services, from pharmaceutical packaging suppliers to specialized logistics providers.
Long-Term Sustainability
While the demand for GLP-1s is currently at an all-time high, skeptics sometimes question the long-term sustainability of such massive manufacturing footprints. However, the technology being installed by Resilience is designed for "platform adaptability." The infrastructure required to manufacture sterile injectables can be repurposed for other biologic drugs or complex therapies in the future, providing a hedge against shifting medical trends.
Conclusion
The $750 million investment by Resilience and Eli Lilly is a clear signal that the era of chronic disease management through advanced injectables is only in its infancy. By betting on American manufacturing, these companies are not only addressing the immediate needs of millions of patients but are also setting a new standard for how the pharmaceutical industry can rapidly scale to meet the demands of the 21st century. As construction begins and the hiring process for the 400 new roles accelerates, the eyes of the global biotech sector will remain firmly fixed on the transformation unfolding in the heart of Ohio.
About the Author
